STOCK TITAN

Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Firefly Neuroscience (NASDAQ: AIFF) reported a 373% year-over-year increase in commercial Evoke scan utilization among patients under age 18. The FDA-510(k)-cleared platform assesses brain function, and the reported growth covers patients exhibiting symptoms of ADHD, attention or focus deficits.

Building on its September 2026 commercial agreement with NeuroSigma, Firefly is using its nationwide clinician network to distribute the Monarch eTNS System, an FDA-cleared, non-drug prescription treatment for pediatric ADHD. The company aims to connect diagnostic assessments with treatment in a diagnostic-to-treatment revenue model. Firefly also has a proprietary repository of over 200,000 standardized EEG/ERP brain scans, which it believes strengthens its artificial intelligence models.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointEvoke commercial scan utilization among patients under 18 with ADHD, attention or focus symptoms increased 373% year over year.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.September 2026 NeuroSigma agreement supports Monarch eTNS distribution through Firefly’s clinician network toward a planned diagnostic-to-treatment revenue model.
  • Minor pointFirefly believes its repository of over 200,000 standardized EEG/ERP brain scans strengthens its artificial intelligence models.

Negative

  • None.

Key Figures

U18 ADHD scan volume growth: 373% year over year Proprietary scan dataset: Over 200,000 standardized EEG/ERP brain scans
U18 ADHD scan volume growth
373% year over year
Commercial utilization of the Evoke platform
Proprietary scan dataset
Over 200,000 standardized EEG/ERP brain scans
Firefly's proprietary data repository

Historical Context

2 past events · Latest: Sep 25
2 events
  1. Sep 25

    ADHD partnership

    24h Move
    +68.9%

    Firefly agreed to introduce Monarch to Evoke clinicians, with NeuroSigma handling training and fulfillment.

  2. Aug 05

    Scan volume growth

    24h Move
    -3.4%

    Evoke scan volumes at TMS-center customers rose 291% year over year.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

510(k), eeg, erp
3 terms
510(k) regulatory
"FDA-510(k)-cleared Evoke™ platform"
A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.
eeg medical
"over 200,000 standardized EEG/ERP brain scans"
An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.
erp medical
"over 200,000 standardized EEG/ERP brain scans"
ERP, or Enterprise Resource Planning, is a comprehensive software system that helps organizations manage and integrate core business processes such as finance, supply chain, and human resources in one unified platform. For investors, ERP systems can indicate how efficiently a company operates; strong and well-integrated systems often suggest good management and potential for sustainable growth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

4.7x expansion in scan volume bodes well for Firefly’s recent commercial partnership to cross-sell non-drug treatment for pediatric ADHD across its growing nationwide network of Evoke™ clinical customers

KENMORE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI) technology, today announced a 373% year-over-year (“YoY”) increase (a 4.7-fold gain) in commercial utilization of its FDA-510(k)-cleared Evoke™ platform for pediatric and adolescent patients (under age 18) exhibiting symptoms of ADHD, attention, or focus deficits.

This accelerated commercial utilization highlights expanding clinical adoption and revenue-generating scale across Firefly's neurodiagnostic platform, which converts complex electrophysiological data into objective brain-function assessments:

• 373% YoY Volume Growth: Rapid organic demand and systematic integration of the Evoke™ platform into routine neuropsychiatric workflows are driving recurring scan utilization.

• 200,000+ Proprietary Scan Dataset: Every scan expands Firefly’s proprietary data repository of over 200,000 standardized EEG/ERP brain scans, which the Company believes strengthens its AI foundation models and long-term competitive moat.

• Commercial Cross-Sell Synergies: Building on its September 2026 commercial agreement with NeuroSigma, Firefly is actively leveraging its nationwide clinician network to distribute the Monarch eTNS® System — the first FDA-cleared, non-drug prescription treatment for pediatric ADHD — with the goal of creating an end-to-end diagnostic-to-treatment revenue model.

"The 373% increase in our pediatric ADHD scan volume reflects what we believe is accelerating market adoption of objective, measurement-driven psychiatry," said Greg Lipschitz, Chief Executive Officer of Firefly Neuroscience. "Our commercial priority is to build on this momentum by helping existing and new clinical partners deploy the Monarch eTNS® treatment alongside the Evoke™ platform across our expanding network."

About Firefly Neuroscience

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence ("AI") company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly's proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world's largest known standardized EEG/ERP repository. Firefly's EEG-based, AI-driven, and FDA-510(k)-cleared Evoke™ System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.

Please visit www.fireflyneuro.com for more information.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" for purposes of the federal securities laws concerning Firefly, including statements relating to Firefly's management team's expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor & Media Contact

Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Firefly Neuroscience’s pediatric Evoke scan utilization grow?

Commercial Evoke scan utilization increased 373% year over year among patients under age 18 exhibiting symptoms of ADHD, attention or focus deficits. Firefly also described the increase as a 4.7-fold gain.

Keep reading